DXCM News and Press, DexCom Inc. From 09/21/22

Summary From 2017 to 2021, sales grew by an average of 36% per year. DexCom is growing strongly, developing and introducing top products to the market, but the stock is still highly valued. The stock has entered a bear market. Introduction DexCom ( DXCM ) has...

Summary The Health Care sector has easily beaten the broad market so far in 2022. One risk-on niche of Health Care is Medical Devices, down sharply this year. DexCom, Inc. is down nearly 50% from its all-time high last year, but the stock still looks expensive. The H...

Bear markets are never fun. Downtrodden equity markets are, however, a great time for investors with a long-term mindset to buy stocks. Keeping with this theme, the 2022 bear market has created a slew of attractive buying opportunities. Cosmetic surgery company InMode (NASDAQ: INM...

Diabetes company DexCom (NASDAQ: DXCM) has been an incredible investment over the past decade. Its 2,500% returns during that time have dwarfed the S&P 500 and its 177% gains. And despite those impressive results, DexCom is still growing and likely will continue to expand fo...

The U.S. Department of Labor announced its latest data on inflation this morning. According to the report, the Consumer Price Index rose by an unsightly 8.3% in August relative to the same period a year ago. U.S. stocks, as a result, are mostly in the red Tuesday morning. Growth-depende...

DexCom ( NASDAQ: DXCM ) said Wednesday it promoted Jake Leach to the role of COO. Leach most recently served as chief technology officer at DXCM since 2018. For further details see: DexCom promotes technology chief Leach to COO

DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today the promotion of Jake Leach to the role of chief operating officer. Leach has most recently served as chief technology officer at Dexcom since 2018...

Summary ResMed has done well to grow its top and bottom lines recently, but this doesn't make the company a great investment prospect. Shares look very pricey at this point in time and should warrant further downside moving forward. This is the case even with current catalysts...

Summary The partnership between Senseonics Holdings and Elevance Health (formerly Anthem) is expected to increase coverage to Senseonics' implantable CGM systems including Eversense. Senseonics plans to introduce new diabetes management systems as well as doctors and patients to t...

On August 15, institutional investment managers with more than $100 million AUM had to disclose their positions at the end of Q2 2022. I curated a list of some high-profile hedge funds and looked into their holdings at the end of June 2022. June was a temporary bottom in the marke...